(Reuters) -Packaging firm Novolex will buy rival Pactiv Evergreen in a $6.7 billion deal, as the Apollo Global Management-owned firm looks to bolster its business of food and beverage packaging in a cautious economic environment. Novolex will offer $18 per share to take Pactiv private in an all-cash transaction, including debt, the companies said on Monday. The deal represents a 32.4% premium to Pactiv's closing price on Dec. 2, a day before Bloomberg News first reported that Novolex was considering purchasing the company. Shares of Pactiv, which sells its products to restaurants, retailers, food and beverage producers, packers and processors, jumped about 19%. Packaging firms have been scouting for deals as easing demand following a boom fueled by e-commerce during the pandemic sparked consolidation in the sector. Last month, Switzerland-based Amcor agreed to buy U.S. peer Berry Global for $8.4 billion. International Paper said in April it would buy British paper and packaging firm DS Smith. Lower sales volumes in the food and beverage merchandising segment even led to a decline in Pactiv's third-quarter revenue last month. The company also reported a loss during the period, hurt by a rise in raw material costs. The Novolex-Pactiv deal, supported by funds managed by affiliates of Apollo and Canada Pension Plan Investment Board, would allow the merged company to deliver 250 brands, along with expanded distribution, across the U.S., Canada and Mexico. The combined firm will be led by Novolex Chairman and CEO Stan Bikulege. Barclays Bank, Morgan Stanley and RBC Capital Markets are the financial advisers to Novolex, while Goldman Sachs and Lazard Freres are advisers to Pactiv. (Reporting by Anuja Bharat Mistry in Bengaluru; Editing by Shilpi Majumdar)
Apollo-owned Novolex to take packaging products maker Pactiv private in $6.7 billion deal
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...